Cell therapy for heart failure: lessons learned from SCIENCE

European Journal of Heart FailureVolume 25, Issue 4 p. 588-590 Invited Editorial Cell therapy for heart failure: lessons learned from SCIENCE Ricardo Sanz-Ruiz, Ricardo Sanz-Ruiz Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), Centro de Investigación Biomédica en Red – Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, SpainSearch for more papers by this authorEmerson C. Perin, Emerson C. Perin The Texas Heart Institute, Houston, TX, USASearch for more papers by this authorFrancisco Fernández-Avilés, Corresponding Author Francisco Fernández-Avilés [email protected] Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), Centro de Investigación Biomédica en Red – Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain Corresponding author. Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), Centro de Investigación Biomédica en Red – Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Tel: +34 91 4265882, Fax: +34 91 5868276, Email: [email protected]Search for more papers by this author Ricardo Sanz-Ruiz, Ricardo Sanz-Ruiz Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), Centro de Investigación Biomédica en Red – Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, SpainSearch for more papers by this authorEmerson C. Perin, Emerson C. Perin The Texas Heart Institute, Houston, TX, USASearch for more papers by this authorFrancisco Fernández-Avilés, Corresponding Author Francisco Fernández-Avilés [email protected] Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), Centro de Investigación Biomédica en Red – Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain Corresponding author. Department of Cardiology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), Centro de Investigación Biomédica en Red – Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Tel: +34 91 4265882, Fax: +34 91 5868276, Email: [email protected]Search for more papers by this author First published: 23 February 2023 https://doi.org/10.1002/ejhf.2807 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2772. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023; 118: 3272– 87. 2Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics – 2021 update: a report from the American Heart Association. Circulation. 2021; 143: e254– 743. 3Borow KM, Yaroshinsky A, Greenberg B, Perin EC. Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure: a review of biological plausibility and implementation of flexible clinical trial design. Circ Res. 2019; 125: 265– 81. 4Braunwald E. Cardiac cell therapy: a call for action. Eur Heart J. 2022; 43: 2352– 3. 5Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, et al. Global position paper on cardiovascular regenerative medicine. Eur Heart J. 2017; 38: 2532– 46. 6Bolli R, Tang XL. The sad plight of cell therapy for heart failure: causes and consequences. J Cardiovasc Aging. 2022; 2: 16. 7Bolli R, Solankhi M, Tang XL, Kahlon A. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. Cardiovasc Res. 2022; 118: 951– 76. 8Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, et al. A phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021; 23: 661– 74. 9Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016; 387: 2412– 21. 10Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015; 36: 1744– 53. 11Bolli R, Tang XL. Clinical trials of cell therapy for heart failure: recent results warrant continued research. Curr Opin Cardiol. 2022; 37: 193– 200. 12 Qayyum AA, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, et al. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial. Eur J Heart Fail. 2023; 25: 576– 87. 13Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Kofoed KF, Haack-Sørensen M, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial. Eur J Heart Fail. 2020; 22: 884– 92. 14Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure should they be used and how? Eur Heart J. 1996; 17: 1629– 39. Volume25, Issue4April 2023Pages 588-590 ReferencesRelatedInformation